Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Bellerophon Therapeutics Inc
Healthcare
P/NCAV
0.15x
Ticker
BLPH
Exchange
Over The Counter
Country
United States
Close
0.06 $
Mkt Cap
559680 $
EV
-3.8M $
NCAV Burn Rate
45.9%
Current Ratio
3.96
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.2x
EV/FCF
0.2x
Dilution
31.8% p.A
Total Net Income
-319.5M $
Cheapness
76.0%
Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company’s focus is to develop its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical development for the therapeutic delivery of inhaled nitric oxide. It is also developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD), PH-Sarcoidosis, PH-chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension, and other pulmonary hypertension conditions. The Company’s subsidiaries include Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average